80 results about "Dispersible tablet" patented technology

Provided herein are high strength / high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.

Provided are an oral pharmaceutical composition containing a PDE4B inhibitor compound as shown in formula (I) and a preparation method therefor. The composition contains the compound of formula (I), a filler, an adhesive, a disintegrant, a solubilizer, and a lubricant. The composition can be prepared into oral preparation forms such as a tablet, a capsule, a granule, and a dispersible tablet, and has the advantages of a high bioavailability, good content uniformity, good stability, easy industrialization, etc.

The invention discloses a dotenorad tablet and a preparation method thereof, belongs to the technical field of medicine preparation, and is used for solving the technical problem that the dissolution rate and the disintegration rate of the dotenorad tablet in the prior art need to be further improved. A preparation method of a dotenorad tablet comprises the following steps: carrying out ball milling on a dispersion liquid by using a planetary ball mill, and carrying out post-treatment to obtain a dotenorad nanocrystal, the Gemini type modified surfactant, the modified chitosan oligosaccharide and the modified xanthan gum are cooperatively introduced, stable dispersion of nanocrystals, uniform forming of a tablet structure and efficient control of a sustained-release coating are achieved, the three components perform their own functions, a stable and controllable drug release system is constructed, the dissolution rate, content uniformity and storage stability of the preparation are effectively improved, and the sustained-release effect of the tablet is improved. And the technical bottlenecks of poor dispersibility, unstable release and the like of the traditional preparation dotenorad tablet are broken through.

The invention discloses a voriconazole dispersible tablet and a preparation method thereof, relates to the technical field of pharmacy, and solves the technical problem of low bioavailability caused by low dissolution rate and slow disintegration speed of the conventional voriconazole dispersible tablet. The voriconazole dispersible tablet comprises 30-50 parts of voriconazole, 10-20 parts of a disintegrating agent, 15-25 parts of a sweetening agent, 3-8 parts of an adhesive, 1-2 parts of a lubricant and 8-16 parts of a pore forming agent, the pore-forming agent comprises beta-tricalcium phosphate and a polyethylene glycol-chitosan grafted copolymer, the pore-forming agent is prepared by performing ultrasonic treatment and freeze-drying on beta-tricalcium phosphate and a polyethylene glycol-chitosan grafted copolymer aqueous solution, and in the pore-forming agent, the polyethylene glycol-chitosan grafted copolymer is adsorbed in pores of beta-tricalcium phosphate; the voriconazole dispersible tablet provided by the invention can accelerate disintegration and dissolution of drugs, improves the dissolution rate and bioavailability of the drugs, and is high in drug stability and low in impurity content.

The invention provides an edaravone dispersible tablet and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, and the preparation method comprises the following steps: taking 52.5% by weight of edaravone, 0.5-5% by weight of a disintegrating agent, 0.5-5% by weight of a flow aid, 0.5-5% by weight of a sweetening agent, 0.25-5% by weight of a lubricant and the balance of a lactose microcrystalline cellulose co-treatment substance, directly and uniformly mixing, and tabletting to obtain the edaravone dispersible tablet. The lactose and microcrystalline cellulose co-treatment material integrates the advantages of lactose and cellulose, the fluidity and compressibility of total mixed powder can be guaranteed, the tablet weight difference of the tabletting process is reduced, the feasibility of mass production is guaranteed, and the production efficiency and the qualification rate of the tabletting process are improved; compared with a traditional solid dispersion process, the method has the advantages that solvent treatment, fluidized bed granulation or high-temperature drying steps are not needed, and preparation production can be completed only through direct mixing and tabletting processes, so that the influence of a humid and hot environment on the API stability is fundamentally avoided, and the product is more stable.

1. Name of the design product: Packaging box (Iron Dextran Dispersible Tablets). 2. Use of the design product: For product packaging. 3. Design key points of the design product: The combination of shape and pattern. 4. Picture or photograph that best shows the design key points: Front view.

The present invention relates to an orodispersible tablet manufactured by a direct compression method comprising Topiramate or pharmaceutically acceptable salts thereof, at least one or more diluents, at least two or more disintegrant, at least one lubricant, at least one glidant, and at least one flavoring agents. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said Orodispersible tablet.

The invention discloses a Shenshuaining dispersible tablet and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The Shenshuaining dispersible tablet provided by the invention has the advantages of being convenient to carry and take and accurate in dosage, is excellent in moisture resistance, is quick to disintegrate, is excellent in dispersion state and is quick to dissolve out, and the bioavailability of the Shenshuaining dispersible tablet is improved. The key points of the technical scheme are as follows: by selecting specific types and dosages of a filling agent, a disintegrating agent and a lubricating agent, the consistency and reliability of the medicine quality are ensured, the disintegration is rapid, the dispersion state is good, the dissolution is rapid, and the dissolution and moisture resistance of effective components of the medicine are greatly improved.

The invention relates to the technical field of nutritional supplement preparations for pets, in particular to a high-activity non-denatured II-type collagen pet joint dispersible tablet and a preparation method thereof. According to the technical scheme, the soft capsule is prepared from the following raw materials in percentage by weight: 4.0%-7.0% of non-modified II type collagen, 4.0%-6.0% of sodium chondroitin sulfate, 4.0%-6.0% of green lip mussel powder, 0.5%-1.5% of sodium hyaluronate, 30%-40% of microcrystalline cellulose, 12%-18% of sodium carboxymethyl starch, 15%-22% of sweet potato starch, 4.0%-6.0% of polyvinylpolypyrrolidone, 6.0%-10.0% of enzymolysis chicken liver powder, 2.0%-4.0% of yeast extract, 1.5%-3.5% of lactose goat milk powder and 0.3%-0.7% of magnesium stearate. A core active component structure is protected by virtue of nano embedding and a whole-course low-temperature process, and a dual joint maintenance path of immunoregulation and nutrition supplement is constructed.

The present invention relates to an orodispersible tablet manufactured by a wet granulation method comprising Famotidine or pharmaceutically acceptable salts thereof, one or more diluents, at least on

The invention discloses a ginkgo dispersible tablet with high dispersion uniformity and a processing technology. The processing technology comprises the following steps: step 1, taking materials; step 2, pretreatment; step 3, primary mixing; step 4, performing three-dimensional mixing; step five, granulating; step 6, post-processing; step 7, tabletting; step 8, coating; according to the ginkgo dispersible tablet, the high-quality ginkgo leaf extract is selected as the raw material, meanwhile, povidone is added to enhance the strength and stability of the tablet, and the granularity specification is controlled in cooperation with multiple times of sieving, so that the prepared ginkgo dispersible tablet has high dispersion uniformity, and the effectiveness and bioavailability of the medicine are guaranteed; residual particle impurities and moisture are removed through pretreatment, so that the purity of the raw materials is guaranteed, and the processing quality of the ginkgo dispersible tablets is improved; during coating treatment, polyvinyl alcohol is selected as a coating material, polyethylene glycol is added as a plasticizer, and coating is performed twice, so that the surface smoothness is improved, coating cracks are prevented, and the disintegration time limit and the dissolution rate of the dispersible tablet are guaranteed.

The invention discloses a ginkgo biloba ketone ester dispersible tablet packaging device which is convenient for controlling the discharging speed, and relates to the technical field of tablet packaging. The device comprises a double-headed motor, a first pulley, a photoelectric switch, a first rotating shaft, a feeding tube, a mounting block, a fourth rotating shaft, a material baffle plate, a magnet, an elastic telescopic rod, a fixed bracket and an electromagnet. The double-headed motor is started, and the output shaft of the double-headed motor drives the first pulley to rotate, so that the second belt is driven, and the second belt drives the mounting block to move. When the mounting block triggers the photoelectric switch, the electromagnet is powered off, so that the electromagnet no longer attracts the magnet, and the elastic telescopic rod pushes the material baffle plate to rotate, so that the ginkgo biloba ketone ester dispersible tablet passes through the feeding tube. The feeding speed of the device can be controlled by controlling the rotation speed of the output shaft of the double-headed motor. When the right end face of the mounting block does not match the left end face of the photoelectric switch, the electromagnet is powered on to close the material baffle plate.

An orodispersible tablet of topiramate with masked bitter taste, comprising: topiramate or pharmaceutically acceptable salt(s) thereof at 20-40 %w / w; a diluent at 35-80 %w / w (e.g., microcrystalline ce

To provide a lisdexamfetamine dimesylate orally dispensible tablet, and to provide a process for preparation thereof.SOLUTION: The process for preparation of the lisdexamfetamine dimesylate orally dispensible tablet includes: co-sieving lisdexamfetamine dimesylate, a binder, and a diluent; dry-mixing and blending the sieved lisdexamfetamine dimesylate, the binder, and the diluent to form a blended dry mixture; co-sieving and blending the diluent, a buffer, a disintegrant, a sweetener, and an antistatic agent to prepare an intermediate blend; blending the blended dry mixture with the intermediate blend; lubricating the blended dry mixture with the intermediate blend to form drug granules ready for compression; and compressing the ready-to-compress drug granules to form a compressed lisdexamfetamine dimesylate orally dispensible tablet.SELECTED DRAWING: Figure 1

The present invention relates to a solid pharmaceutical composition manufactured by a wet granulation method comprising carbidopa and levodopa or pharmaceutically acceptable salts thereof, one or more disintegrant, one or more diluent, at least one binder, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention provides a torasemide dispersible tablet as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations, the torasemide dispersible tablet comprises the following components: torasemide, microcrystalline cellulose, lactose, pregelatinized starch, cross-linked sodium carboxymethyl cellulose and magnesium stearate, the technical problem that a patient is difficult to swallow is solved, and the torasemide dispersible tablet is suitable for clinical application. The technical effects of high stability, rapid disintegration and high dissolution rate are achieved. The torasemide dispersible tablet is stable, easy to swallow, high in disintegration speed after entering a human body and high in bioavailability.

1. Name of the product in this design: Packaging Box (Cefdinir Dispersible Tablets 2). 2. Purpose of this design: Product packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: the front view. 5. The design for which protection is sought includes color.

The application relates to the technical field of tablet presses, in particular to a tablet press for dispersible tablet production, which comprises a base, the top surface edge of the base is integrally formed with a portal frame, the bottom surface middle portion of the base is integrally formed with a bearing frame, the middle portion of the bearing frame is provided with a indexing mechanism, the top end of the indexing mechanism is fixedly connected with a tablet pressing table, one side of the top surface of the base is fixedly connected with a mounting flap, the middle portion of the mounting flap is rotatably connected with a transmission mechanism, the transmission mechanism is connected with a tablet pressing mechanism, the two sides of the tablet pressing mechanism are provided with cleaning mechanisms, the top rear side of the portal frame is fixedly provided with a material adding mechanism, and one side of the tablet pressing mechanism is movably connected with a material taking mechanism. The improved tablet press carries out tablet pressing through the tablet pressing mechanism, the cleaning mechanism is automatically cleaned by the extrusion plate when the tablet pressing mechanism operates, the transmission mechanism transmits the power of the indexing mechanism to the material taking mechanism and the material adding mechanism, and automatic material taking and automatic material adding are realized.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a radix gentianae liver-purging solid dispersible tablet and a preparation method thereof. The radix gentianae liver-purging solid dispersible tablet is prepared from the following components in parts by weight: 20 to 40 parts of radix gentianae liver-purging thick paste, 0.4 to 0.6 part of radix bupleuri-radix angelicae sinensis volatile oil, 31 to 56 parts of a water-soluble polymer dispersion carrier, 0.8 to 2.4 parts of an inclusion agent, 8 to 16 parts of a disintegrating agent, 18 to 31 parts of a diluent, 7 to 18 parts of an adhesive, 0.5 to 2 parts of a flow aid and 0.3 to 0.8 part of a lubricating agent, the radix gentianae liver-purging solid dispersible tablet provided by the invention can be quickly disintegrated and released, quickly exerts a treatment effect, corrects a damp-heat state of liver and gallbladder, and quickly improves clinical symptoms of damp-heat of liver and gallbladder, dizziness, hot eyes, tinnitus, deafness, hypochondriac pain, bitter taste in the mouth, red and astringent urine and damp-heat leukorrheal.

The present invention relates to an orodispersible tablet of rivaroxaban having overall improved characteristics. its process of manufacturing and its use as anticoagulant.

This invention provides a controllable tableting device for nabumetone dispersible tablets and the resulting nabumetone dispersible tablets, belonging to the field of pharmaceutical processing equipment. It includes a feed shell and vertical tubes. The feed shell is annularly arranged with several vertical tubes evenly distributed and fixedly connected to its bottom surface. Each vertical tube contains a feed assembly. A collection shell is installed on the lower side of each vertical tube. The lower sides of several collection shells are movably connected to the same circular shell, and a fixing plate is fixedly connected to the side wall of the collection shell. This invention uses an electric push rod to drive the annular plate, which in turn drives a movable plate via a connecting plate. The movable plate, in turn, drives a first push plate via a circular rod, extending the first push plate to a suitable length within the circular shell. When the collection shell rotates, the first push plate controls the movement length of the movable rod, thereby controlling the tableting specifications of the nabumetone dispersible tablets to meet the needs of producing different specifications of nabumetone dispersible tablets.

The invention discloses an improved production device and process of voglibose dispersible tablets. The device comprises a central control box, an extruder shell, a heating pipe, a speed reducer and a stirrer, the process comprises the following steps: 1, selecting and matching raw materials; 2, performing hot-melt extrusion on the raw materials; 3, crushing and filtering the raw materials; step 4, adding chemicals and stirring; step 5, tabletting and forming the medicines; and step 6, finished product detection and quality control. And step 7, packaging and selling finished products. According to the invention, a novel medicine treatment device is designed, raw materials are processed by adopting a hot-melt extruder, the voglibose with indissolvability is heated at high temperature in the device, and the voglibose and copovidone with a certain proportion are uniformly mixed, so that the indissolvability voglibose can be effectively and quickly melted and extruded, and the voglibose can be quickly melted and extruded; other special treatment is not needed, so that the addition of device components is reduced, the preparation cost of medicines is controlled, and the selling price of subsequent medicines is reasonably reduced.

The invention provides an iron-dextran dispersible tablet and a preparation method thereof, and relates to the technical field of medicines.The preparation method comprises the steps that iron-dextran and nanoscale vitamin C are mixed and ground, and a main medicine compound is obtained; dissolving poloxamer 407 in an ethanol-glycerol mixed solvent, stirring until the poloxamer 407 is completely dissolved, adding the main drug compound, and carrying out ultrasonic dispersion to form a uniform suspension; the preparation method comprises the following steps: dissolving carboxymethyl chitosan-beta-cyclodextrin in ethanol, stirring until the solution is clear, sequentially adding polyvinylpolypyrrolidone and a sodium bicarbonate-citric acid effervescent pair, carrying out ultrasonic dispersion, filtering a membrane, and adjusting the viscosity to obtain a mixed solution; respectively taking the suspension and the mixed solution as medicine ink and disintegrating agent ink, printing a medicine layer and a disintegrating agent layer by utilizing an ink-jet printing technology to obtain a tablet, and sequentially performing freeze drying and surface nanofiber treatment on the tablet to obtain the iron-dextran dispersible tablet. The problem that the iron dextran dispersible tablet cannot be quickly disintegrated in the prior art is solved.

The invention discloses a pharmaceutical composition for preventing and treating joint inflammation / relieving pain and a preparation method thereof. The pharmaceutical composition comprises the following components: 1, glucosamine sulfate 2KCL (99%), 2, chondroitin sulfate, 3, methylsulfonylmethane (MSM), 4, type II collagen, 5, a morinda officinalis root extract, 6, a herba epimedii extract, 7, a sambucus williamsii extract, 8, a rhizoma drynariae extract, 9, a turmeric root extract, 10, hyaluronic acid and 11, chitosan. The pharmaceutical composition can be prepared into tablets, capsules, dispersible tablets, chewable tablets, effervescent tablets, buccal tablets and other oral preparations. The composition has the effect of preventing and relieving knee joint inflammation / pain.

The present invention relates to a pharmaceutical composition comprising nor-UDCA or a pharmaceutically acceptable salt or ester thereof and a process for its preparation. The present invention most preferably discloses a solid oral dosage form of nor-UDCA, preferably in the form of tablets, capsules, disintegrating tablets and effervescent tablets.

An orodispersible solid pharmaceutical composition in tablet form is disclosed comprising a) carbidopa and levodopa or pharmaceutically acceptable salts thereof, b) one or more diluent, c) one or more

The invention provides a water dispersible granule containing bicyclopyrone and pyroxasulfone, which is prepared from the following components in percentage by mass: 20 to 50 percent of active pharmaceutical ingredients, 2 to 12 percent of dispersing agent, 2 to 8 percent of wetting agent, 5 to 20 percent of stabilizing agent and filler, the active ingredients comprise pyroxasulfone and bicyclopyrone or salts of the pyroxasulfone and the bicyclopyrone. The content of the bicyclopyrone-pyroxasulfone water dispersible granule provided by the invention is more than 35%, so that the dosage and the application frequency of herbicides are reduced, and the medicament cost is reduced. By optimizing the auxiliaries, the processing difficulty of the dosage form is greatly reduced, the dispersible tablet has the advantages of quick disintegration and high suspension rate, the product stability is improved, the dispersible tablet can tolerate thermal storage at 54 DEG C, the influence of environmental change in the transportation process is effectively solved, and the product quality problem of unstable thermal storage is avoided. And meanwhile, the method can tolerate different water qualities such as C water, D water, 3WHO water and the like, can be used in different countries and regions, and is beneficial to large-scale popularization and application.

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.